Stryker (NYSE:SYK) Insider Dylan Bram Crotty Sells 441 Shares of Stock

Stryker Corporation (NYSE:SYK) insider Dylan Bram Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Stryker Trading Down 0.2%

NYSE SYK opened at $330.08 on Thursday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The firm has a market capitalization of $126.61 billion, a PE ratio of 34.21, a P/E/G ratio of 2.11 and a beta of 0.76. The stock’s 50 day moving average is $328.37 and its 200 day moving average is $331.72.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the prior year, the firm posted $3.13 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Institutional Investors Weigh In On Stryker

A number of hedge funds and other institutional investors have recently bought and sold shares of SYK. Amundi increased its holdings in shares of Stryker by 18.3% during the second quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock valued at $392,402,000 after acquiring an additional 192,447 shares in the last quarter. HighTower Advisors LLC raised its position in shares of Stryker by 8.3% in the 2nd quarter. HighTower Advisors LLC now owns 486,005 shares of the medical technology company’s stock valued at $153,014,000 after purchasing an additional 37,269 shares during the last quarter. Advus Financial Partners LLC boosted its stake in Stryker by 25.1% in the 2nd quarter. Advus Financial Partners LLC now owns 802 shares of the medical technology company’s stock worth $253,000 after purchasing an additional 161 shares in the last quarter. Groupe la Francaise boosted its stake in Stryker by 16.7% in the 2nd quarter. Groupe la Francaise now owns 21,000 shares of the medical technology company’s stock worth $6,613,000 after purchasing an additional 3,000 shares in the last quarter. Finally, California State Teachers Retirement System grew its position in Stryker by 30,523.4% during the 2nd quarter. California State Teachers Retirement System now owns 163,395,348 shares of the medical technology company’s stock worth $51,443,391,000 after purchasing an additional 162,861,784 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on SYK shares. Citizens Jmp reduced their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a report on Monday, August 3rd. JPMorgan Chase & Co. lowered their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a report on Friday, July 31st. The Goldman Sachs Group reiterated a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. Citigroup restated a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. Finally, Evercore set a $350.00 price objective on Stryker in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.